Global Leader in Women’s Health Recognized with Three IMV ServiceTrak™ Awards for Mammography During RSNA 2022
Hologic, Inc., an innovative medical technology company primarily focused on improving women’s health, swept the 2022 IMV ServiceTrak™ Awards for Mammography, taking home awards for Best Service, Best Customer Satisfaction and Best System Performance. This is the 10th consecutive year that Hologic has ranked first in the industry for Mammography System Performance and Customer Satisfaction and the eighth year for Mammography Service.
“We are thrilled to win the IMV Award for a 10th year and need to acknowledge our outstanding service team that has kept us on top of the IMV leaderboard,” said Erik Anderson, President of the Breast and Skeletal Health Solutions Division at Hologic. “Because of their focus and dedication, we’ve delivered exceptional outcomes and experiences for our customers and the patients they serve. We look forward to the next 10 years.”
Hologic is the company behind the Genius®3D Mammography™ exam, the only mammogram approved by the FDA as superior to conventional mammography for all women, including those with dense breasts.1 It also detects 20%-65% more invasive breast cancers compared to 2D mammography alone.2
SureCare® Service from Hologic offers a variety of service plans designed to help customers get the most out of their systems. SureCare plan options include maximum uptime guarantees, predictive analytics* to address equipment issues before they occur and state-of-the-art connectivity to provide real-time insights on optimizing business and clinical outcomes.
Hologic’s strong team of veteran service and support experts includes factory-trained field engineers solely focused on servicing Hologic systems and highly qualified clinical applications specialists who assist new users along every step of setup, on-site training and beyond.
“We are honored to receive this recognition from IMV once again as it underscores the team’s partnership with our customers,” said Mark Horvath, Corporate Vice President, Global Services. “We are deeply committed to supporting our customers through our SureCare Service offerings so they can focus on what’s most important – providing exceptional care to their patients.”
To learn more about SureCare Service from Hologic, visit www.Hologic.com/SureCare-Service.
Click here for the latest Women's Health news
Source: Hologic
References:
1 FDA Approvals P080003, P080003/S001, P080003/S004, P080003/S005
2 Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions ® on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D Mammography™ System versus women receiving 2D FFDM mammograms only.
